Key result
Novel multitarget drug scaffolds show therapeutic potential across cardiac diseases.
Why the study?
Recent advances in multitarget drugs for cardiac diseases require synthesis and evaluation of emerging molecular scaffolds and their pharmacological properties.
This review outlines the principles of cardiac polypharmacology and multitarget drug design, highlighting key structural features and the therapeutic potential of emerging compound classes.
This review provides an overview of recent advances in the development of multitarget drugs (MTDs) for cardiac diseases, with a particular focus on emerging molecular scaffolds and their pharmacological properties. We discuss the fundamental principles of cardiac polypharmacology and multitarget drug design, highlighting key compound classes, such as 1,4-benzothiazepines, 1,4-dihydropyridines (DHPs), and polyphenol derivatives. Particular emphasis is placed on the relationship between the structural features and the pharmacological activity, efficacy, and therapeutic potential of these compounds.
No takes yet. Share an insight, caveat, or question.
Mitronova et al. (2026) conducted a review in cardiovascular disease. Multitarget drugs was evaluated. Multitarget drug design for cardiac diseases is advancing with emerging molecular scaffolds like 1,4-benzothiazepines, 1,4-dihydropyridines, and polyphenol derivatives showing therapeutic potential.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: